Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

计划入组 3,960 人 · 首次发布于 2023 年 5 月 30 日

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

计划入组 102 人 · 首次发布于 2023 年 8 月 9 日

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

计划入组 30 人 · 首次发布于 2020 年 7 月 9 日

Oncoquest-Ovarian

Ovarian(OncoTartis)

DCVax-Ovarian

METABOLIC THERAPY, INC.

United States

Everads Therapy Ltd.

Israel

ATI Physical Therapy

United States

Ovarian Function Suppression Enhances Survival in Select HER2-Positive Breast Cancer

Breast Cancer Index Test Shows Promise for Identifying Low-Risk Premenopausal Patients Who May Avoid Aggressive Therapy

Regulatory T Cell Therapy Unexpectedly Promotes Pathogenic Th17 Cell Generation Through IL-2 Suppression